Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meeting
DNTH•Dianthus Therapeutics said it will present an interim analysis from the Phase 3 CAPTIVATE trial of claseprubart in CIDP at the 2026 AANEM meeting, highlighting broad functional improvement and a favorable benefit-risk profile.
1. Upcoming CIDP analysis
Dianthus Therapeutics flagged clinical updates for its complement inhibitor claseprubart, including a future presentation of interim results from the Phase 3 CAPTIVATE trial in CIDP at the 2026 AANEM annual meeting. The analysis will highlight broad functional improvement and a favorable benefit-risk profile.
2. Myasthenia gravis results
The company also reported that Phase 2 MaGic open-label extension results in generalized myasthenia gravis showed sustained disease control with continued tolerability. Additional presentations will discuss minimal symptom expression and positioning versus downstream complement blockade.
